Bayer Switzerland: Pharmaceuticals

Innovations for health of the future

The changing demographics pose new challenges for healthcare: chronic and multiple coexisting diseases are on the rise, while people are also taking on a more active role in their health management. Bayer Switzerland is meeting these challenges with innovative therapies that offer real therapeutic benefits to patients, while adhering to the high standards of doctors and payers.

Zurich serves as the base for our local business, while Basel has been the global site for our key therapeutic areas of oncology, ophthalmology, and hematology since 2012.

Our therapy areas in Switzerland

Eye disorders
Women’s health
Hematology
Cardiovascular disease
Infectious diseases
Cancer
Pulmonary hypertension
Men’s health
Neurology

Transparency through clinical research In 2020, Bayer (Schweiz) AG began publishing the results of clinical studies on drugs that are approved on the Swiss market and contain new active ingredients. We have compiled the links to these results in the following document, which we will update as and when necessary.

Nubeqa clinical study results (PDF 85.72 KB)

Verquvo clinical study results (PDF 133.59 KB)

Kerendia clinical study results (PDF 117.2 KB)

(Overview from April 12, 2023)

You can find further information about the clinical studies conducted by Bayer here.

PP-OTH-CH-0074-1 2406